Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'

Can CAVA's 2024 Cohort Support Its Next Phase of Unit Growth?

CAVA Group is experiencing strong performance from its newer restaurant locations, with its 2024 cohort generating double-digit same-store sales and representing its highest-performing vintage. The company ended Q2 2026 with 476 restaurants and new unit productivity above 100%, supporting its target of 75-77 net new restaurants in 2026. Meanwhile, competitors Chipotle and Sweetgreen are taking different expansion approaches, with Chipotle maintaining aggressive growth and Sweetgreen adopting a more conservative strategy.

Neoclouds Shine in AI Build Out

Neocloud companies CoreWeave and Nebius reported strong earnings with massive revenue growth (112% and 454% YoY respectively), but both operate at net losses with heavy infrastructure spending. While demand from hyperscalers like Meta and Alphabet is robust, concerns remain about sustainability given high debt costs (11% yields), reliance on short-term contracts as a bridge to long-term capacity, and commodity-like pricing dynamics. The sector shows promise but faces valuation and financing challenges.

Booking vs. CAVA: Comparing Total Scale and Growth Trajectories in Quarterly Revenue Trends

Booking Holdings commands a significantly larger revenue base ($28B TTM) with 13% year-over-year growth, while CAVA demonstrates faster growth at 27% TTM revenue ($1.4B), though from a much smaller scale. Both companies show consistent year-over-year revenue growth despite quarterly fluctuations. Booking's established position in the travel industry and Connected Trip expansion strategy position it for continued long-term growth, while CAVA's early-stage restaurant expansion presents significant upside potential as it scales its hundreds of locations.

DA Davidson Maintains Neutral on Cava Group, Lowers Price Target to $75

DA Davidson analyst Matt Curtis maintains Cava Group (NYSE:CAVA) with a Neutral and lowers the price target from $84 to $75.

Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.

ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.